Abstract There is increasing evidence suggesting that higher intakes of fish or n-3 polyunsaturated fatty acids supplements may decrease the risk of preterm delivery (PTD). We hypothesized that genetic variants of the enzymes critical to fatty acids biosynthesis and metabolism may be associated with PTD. We genotyped 231 potentially functional single nucleotide polymorphisms (SNPs) and tagSNPs in 9 genes (FADS1, FADS2, PTGS1, PTGS2, ALOX5, ALOX5AP, PTGES, PTGES2, and PTGES3) among 1,110 black mothers, including 542 mothers who delivered preterm (\37 weeks gestation) and 568 mothers who delivered full-term babies (C37 weeks gestation) at Boston Medical Center. After excluding SNPs that are in complete linkage disequilibrium or have lower minor allele frequency (\1%) or call rate (\90%), we examined the association of 206 SNPs with PTD using multiple logistic regression models. We also imputed 190 HapMap SNPs via program MACH and examined their associations with PTD. Finally, we explored gene-level and pathway-level associations with PTD using the adaptive rank truncated product (ARTP) methods. A total of 21 SNPs were associated with PTD (p value ranging from 0.003 to 0.05), including 3 imputed SNPs. Gene-level ARTP statistics indicated that the gene PTGES2 was significantly associated with PTD with a gene-based p value equal to 0.01. No pathway-based association was found. In this large and comprehensive candidate gene study, we found a modest association of genes in fatty acid metabolism pathway with PTD. Further investigation of these gene polymorphisms jointly with fatty acid measures and other genetic factors would help better understand the pathogenesis of PTD.
Introduction
Preterm delivery (PTD, \37 weeks of gestation) is a leading cause of infant mortality and morbidity. Despite
Electronic supplementary material The online version of this article (doi:10.1007/s00439-011-1079-5) contains supplementary material, which is available to authorized users. considerable research and progress, the underlying causes and pathogenesis remain unclear, and the rate of PTD remains high in the US at about 12.3% in 2008 (Martin et al. 2010) .
One interesting but unsettled area is the role of fatty acids in PTD. Linoleic acid (LA: 18:2n-6) and a-linolenic acid (ALA: 18:3n-3), the only two known essential fatty acids, are desaturated and elongated into longer chain n-6 (e.g., arachidonic acids (AA: 20:4n-6)), n-3 (e.g., eicosapentaenoic acid (EPA: 20:5n-3) and docosahexaenoic acid (DHA: 22:6n-3)) polyunsaturated fatty acids (PUFAs), respectively, and then into biologically functional eicosanoids: a series of prostaglandins (PGs) and leukotrienes (LTs). AA, EPA, and DHA are critical components of phospholipids and cell membranes, and thus are involved in the integrity and function of the membrane. Furthermore, bioactive products of these PUFAs can regulate blood pressure, blood viscosity, vasoconstriction, and immune and inflammatory responses (Yashodhara et al. 2009 ). However, the eicosanoids, derived from n-3 and n-6 PUFAs, exert different effects. Specifically, the metabolites of arachidonic acids (AA: 20:4n-6), including PGE 2 , PGF 2a , thromboxane A2 (TXA 2 ), 5-hydroxyeicosatetraenoic acid (5-HETE), LTD 4 , and LTC 4 , have been demonstrated to be involved in connective tissue synthesis and breakdown as well as uterine contractions, and thus are important mediators of the parturition process (Allen and Harris 2001; Greenberg et al. 2008) . Metabolic products from n-3 fatty acids (i.e., EPA and DHA), on the other hand, can down regulate the production of the above mediators and hence their downstream effects (Calder 2009 ). DHA also has been shown to give rise to resolvin Ds and protectin D1, newly identified anti-inflammatory lipid mediators (Bazan 2007) . As such, imbalanced PUFAs intake, particularly lower n-3 PUFAs intake, will lead to a high n-6/n-3 ratio and thus may increase the risk of PTD.
Previous studies, although not all, have demonstrated that higher fish or n-3 PUFAs supplement intake may decrease the risk of PTD or increase gestational length (Coletta et al. 2010; Decsi 2009; Guldner et al. 2007; Horvath et al. 2007; Makrides et al. 2006; Oken et al. 2004; Olsen and Secher 2002; Szajewska et al. 2006) . However, these researches have mainly focused on the relationship between dietary/supplemental intake of fatty acids and PTD. The influence of genes involved in fatty acid metabolic pathways on PTD is largely unexplored. In this report, we conducted a comprehensive pathway-based association study to evaluate the association of fatty acid metabolism gene polymorphisms with PTD in a large US black population. Specifically, we examined SNPs in nine genes, which are well known to be involved in the polyunsaturated fatty acid metabolism pathway (details are included under methods), including fatty acid desaturase 1 and 2 (FADS1 and FADS2), cyclooxygenase-1 and cyclooxygenase-2 (PTGS1 and PTGS2), 5-lipoxygenase and its activating protein (ALOX5 and ALOX5AP), and prostaglandin E synthases (PTGES, PTGES2, and PTGES3). To our knowledge, this is the first study of this kind in an inner city black population, which is at a high risk of PTD (Martin et al. 2010) and is known for a higher consumption of LA, AA, and EPA than are whites (Lovejoy et al. 2001 ).
Materials and methods

Study subjects
This study focused on 1,110 black mothers (African Americans and Haitians) who have been enrolled in the Boston Medical Center (BMC) since 1998. This included 542 mothers who delivered a singleton live baby at \37 gestational weeks (66% spontaneous PTD), and 568 mothers who delivered a term singleton baby (C37 gestational weeks) with birth weight greater than 2,500 g. Gestational age was assessed based on the first day of the last menstrual period as recorded in the maternal medical record and the early (\20 weeks) prenatal ultrasound as detailed in previous publications (Tsai et al. 2008; Wang et al. 2002) . The Children's Memorial Hospital Institutional Review Board (IRB) in Chicago and the Boston University Medical Center IRB approved the study protocol. All participating mothers signed written informed consent.
We collected comprehensive epidemiological and clinical data, using standardized questionnaires and maternal and infant medical records, such as maternal age, prepregnancy body mass index (BMI), maternal smoking at 3 months pre-pregnancy and at each trimester, maternal alcohol drinking, and infant gender. In addition, maternal venous blood, cord blood samples and placental specimens were collected.
Candidate genes selection
Many genes are known to be involved in the PUFAs metabolism pathway and many other genes are yet to be discovered. We chose to examine nine genes that are critical to the synthesis of long-chain PUFAs and the derived eicosanoids (e.g., prostaglandins and leukotrienes) (Glaser et al. 2010 ). Specifically, we selected genes FADS1 and FADS2, which encode the two known desaturases converting the essential fatty acids (LA and ALA) to their long-chain derivatives (AA, EPA, and DHA). Numerous studies have demonstrated that the genetic variants in these two genes contribute to the variation of PUFAs in plasma, RBCs, or breast milk (Glaser et al. 2010; Merino et al. 2010) , and thereby could impact the productions of biologically functional eicosanoids and the development of PTD. We also selected the genes encoding the cyclooxygenases (PTGS1 and PTGS2), and the lipoxygenase and its activating protein (ALOX5 and ALOX5AP), which are involved in converting the above derived long-chain PUFAs to the series of PGs and LTs. Finally, we selected three known prostaglandin E synthases (PTGES, PTGES2, and PTGES3) needed in the synthesis of PGE2, the most common prostanoid with the ability to stimulate uterine contractility (Allen and Harris 2001; Glaser et al. 2010; Hara et al. 2010; Merino et al. 2010 ).
SNP selection and genotyping
We selected the potentially functional SNPs and tagSNPs of nine fatty acids metabolism genes. Specifically, we focused on the validated common SNPs (minor allele frequency (MAF) [5%) that have been predicted to be functional variants based on the bioinformatics tool PupaSuite (http://pupasuite.bioinfo.cipf.es/). For example, SNPs result in nonsynonymous amino acid change, SNPs in putative transcription factor binding sites, exonic splicing enhancers, exonic splicing silencers, microRNAs and their targets, DNA triplex, etc. Genotype tagSNPs, which capture existing patterns of genotypes for all of the SNPs of a gene, were identified through the HapMap Project (http:// www.hapmap.org). We chose a minimal set of tagSNPs such that each unselected SNP would be in high linkage disequilibrium (LD) (r 2 C 0.8) with the tagSNPs in a Yoruban population using a pair-wise tagging approach in the Tagger program (de Bakker et al. 2005) . Functional SNPs were preferentially included as tagSNPs whenever possible. Of note, for each gene we selected SNPs from an extended region 5 kb upstream from the 5 0 end and 2 kb downstream from the 3 0 end of the gene region (HapMap Data Rel24/phaseII Nov08).
A total of 231 SNPs (Table S1 ) were genotyped using MassArray Ò technology exemplified by Sequenom (San Diego, CA) at the University of Chicago Core Facility. The blind reproducibility rate was [99.9% based on 56 duplicates and 4 triplicates.
Statistical methods
We tested Hardy-Weinberg equilibrium (HWE) and SNP-SNP correlations using the program HAPLOVIEW (Barrett et al. 2005 ) among 568 mothers who delivered a term baby. We excluded SNPs that are in complete linkage disequilibrium (LD, n = 6) or have lower MAF (\1%, n = 6) or call rate (\90%, n = 13). No SNP was dropped due to the deviation from HWE (p \ 0.001). With a total of 206 SNPs, we conducted systematic association tests for the risk of PTD, including single-SNP association tests using typed and imputed SNPs, a gene-based pathway association test, and haplotype analysis.
We tested the association between each SNP and PTD using a logistic regression model after adjustment for maternal age (\20, 20-24, 25-30, 30-35 , C35 years), education (\high school, high school, some college and above), parity (0, 1, C2), marital status, maternal active smoking, passive smoking, alcohol drinking and drug use during pregnancy, maternal pre-pregnancy BMI (\20, 20-24, 25-30, C30) , and infant gender. Four genetic models (i.e., general, dominant, recessive, and multiplicative) were tested, and results from the general and bestfitted models were reported. We defined the best-fitted model as the one with the lowest v 2 goodness-of-fit test statistics.
To further increase our SNP coverage of the candidate genes, we imputed untyped HapMap SNPs (i.e., Rel24/ phaseII Nov08 and PhaseIII/Rel#2) using MACH (v1.) (Li et al. 2009 (Li et al. , 2010 based on the available genotype data of 206 SNPs. We then applied MACH2DAT to test the association between imputed dosage data (i.e., not an integer copy of an allele with consideration for imputation uncertainty) and PTD. For those significant SNPs identified from MACH2DAT, we presented the associations of their 'best-guess' genotypes (i.e., 0, 1, 2 copies of allele) with PTD following the statistical tests above for the typed SNPs.
Finally, we summarized the associations between each gene and then the pathway with the risk of PTD using the adaptive rank truncated product (ARTP) methods (Yu et al. 2009a ). Specifically, we permutated the preterm status 10,000 times and performed association tests for the 206 typed SNPs for each permutated data set. This leads to the empirical distribution of p values under the situation of no association, and as such the gene-level and pathway-level ARTP statistics are robust to the multiple comparisons. For the genes with significant gene-based p values, we further conducted two-locus and three-locus haplotype analyses via sliding window using an R package haplo.stats (Schaid et al. 2002) .
Results
Characteristics of study subjects
This study consisted of 1,110 black mothers who delivered babies at BMC, including 542 PTD cases and 568 term controls. Compared to mothers with term babies, those with premature babies were more likely to be less educated, unmarried, active and passive smokers during pregnancy, and illicit drug users (p \ 0.05) ( Table 1) . No statistically significant difference across term status was noted with regards to parity, infant gender, maternal age, pre-pregnant BMI, or alcohol drinking. All of these variables were considered to be potential confounders/risk factors and were included in the following regression analyses.
Genetic associations of typed and imputed SNPs with PTD Table 2 summarizes the information on nine tested genes, including the regions of focus in the present study, and numbers of typed and imputed HapMap SNPs (detailed in Supplementary Table 1 ). The mean densities for typed and Table 3 lists twenty-one SNPs that were significantly associated with PTD at the nominal level of 0.05 based on the best-fitted models. The most statistically significant associations were observed in gene ALOX5, including four typed SNP (rs745986, rs7089406, rs4540799, and rs10751382) and one imputed SNP (rs3780900). Specifically, mothers carrying the T allele of rs4540799 had a higher risk of PTD than those carrying the CC genotypes (OR = 1.57, 95%CI: 1.17-2.10, p = 0.003). A similar association was found for three SNPs. None of these typed SNPs had any predicted function based on two bioinformatics tools: PupaSuite and FuncPred (Table 3 footnote) . For gene PTGES2, three out of seven typed SNPs showed significant associations with PTD. Mothers with the CC genotype of the potentially functional SNPs (rs4837243 and rs7047254) were more likely to develop PTD than non-CC carriers with ORs of 3.53 (95%CI: 1.35-9.27) and 1.37 (95%CI: 1.01-1.97), respectively. A marginally significant association was observed for a tagSNP (rs7862523) and PTD (OR = 0.72, 95%CI: 0.52-0.98). It should be noted that none of the associations were significant after correcting for multiple testing based on Bonferroni correction. These significant findings were not materially changed when ancestral proportion estimates were included in the regression model (Table S2a) . Of note, only 923 of the studied subjects had such information available from the Illumina panel of 1,509 African ancestry informative markers (unpublished data). The results also were not substantially changed when analyzing PTD subgroups: 391 PTD subjects who delivered between 32 and 37 weeks of gestation [PTD (32-37 weeks)] or 361 spontaneous PTD mothers who delivered as a result of spontaneous cervical effacement and dilation or premature rupture of membranes without uterine contractions (Table S2a) . We also explored the associations among PTD with placental histologic evidence of intrauterine inflammation (n = 126, defined in a previous study (Gupta et al. 2007 )), PTD subjects who delivered \32 weeks of gestation [PTD (\32 weeks)] (n = 151), and medically indicated PTD (n = 181) (Table S2b) ; however, some estimates might not be reliable due to the small sample size.
Gene-based association and haplotype test of association Figure 1 shows the associations between the typed SNPs and PTD. The gene-based p value derived from ARTP methods was only significant for gene PTGES2 (p = 0.01), and pathway-level test statistic was not statistically significant (p = 0.06). Two-locus and three-locus haplotype association tests for gene PTGES2 did not provide additional or more significant associations compared to the single-SNP test (Fig. 2) .
Discussion
Imbalanced PUFAs intake has been demonstrated to be associated with PTD, but not in all of the studies to date. Lower fish intake in early pregnancy was found to increase the risk of PTD in a prospective cohort of Danish women (Olsen and Secher 2002) , but not in other studies in the Danish population (Kesmodel et al. 1997; Olsen et al. 1990 Olsen et al. , 1995 . Although randomized controlled trials (RCT) and studies using biomarkers for PUFAs also showed \20, 20-24, 25-30, 30-35, C35 years) , education (\high school, high school, and some college and above), parity (0, 1, C2), marital status, maternal active smoking, passive smoking, alcohol drinking and drug use during pregnancy, maternal pre-pregnancy BMI (\20, 20-24, 25-30, C30) , and infant gender. p values were based on Wald test without adjustment of multiple comparisons d Imputed HapMap SNPs conflicting results (Bonham et al. 2008; Horvath et al. 2007; Makrides et al. 2006; Olsen et al. 1991; Pontes et al. 2006; Reece et al. 1997; Szajewska et al. 2006) , metaanalyses of RCTs have demonstrated that n-3 long-chain PUFAs supplementation during pregnancy was associated with prolonged gestation (Makrides et al. 2006; Szajewska et al. 2006) . Individual variations in genetic susceptibility may be one of the explanations for these inconsistent findings, given the mounting evidence for the effect of gene-environment (G 9 E) interactions on the risk of PTD (Crider et al. 2005; Macones et al. 2004; Tsai et al. 2008; Wang et al. 2002; Yu et al. 2009b) . If the gene-fatty acid interactions do exist, then genetic polymorphisms themselves could have moderate marginal effects on PTD and thereby be detected by an association study alone. In this large US black population, we found modest associations between gene polymorphisms in enzymes critical to fatty acids metabolism and the risk of PTD. In addition, the significant SNP-based and gene-based associations for gene PTGES2 and PTD suggested that membrane-associated PGE synthase-2 (PTGES-2) might play important roles in total PGE 2 production and hence the risk of PTD. Three forms of PGE synthases have been previously known and well-studied (Hara et al. 2010; Murakami and Kudo 2004) . The observations of constitutive expression PTGES2 in contrast to stimulus-inducible PTGES expression suggested that the former may have more important effects on PGE 2 production than the latter. However, PGE 2 levels in several tissues were not altered in PTGES2-deficient mice (Jania et al. 2009) , which indicated that PTGES2 may not be an essential enzyme in PGE 2 synthesis. A non-synonymous SNP (rs13283456: Arg298His) in gene PTGES2 was reported to be associated with the parameters of the metabolic syndrome , type II diabetes Nitz et al. 2007) and BMI (Fischer et al. 2009) , and thus support the biological relevance of PTGES2 to inflammation and insulin sensitivity, which also are part of the biological mechanisms underlying the pregnancy complications of PTD. The effect of rs13283456 on PTD is unknown; it was not included in our original SNP selection due to low MAF in Africans (\5%) and was dropped from the imputed SNPs list due to low imputation quality (rsq \ 0.3). In turn, our study demonstrated that two other SNPs in PTGES2 (rs4837243 and rs7047254) not only were significantly associated with PTD, but also appeared to be pronounced among spontaneous PTD, PTD (\32 weeks), and PTD with placental histologic evidence of intrauterine inflammation (Table S2a and S2b) . PTD accompanied by histologic chorioamnionitis was shown to be significantly correlated with spontaneous and PTD (\32 weeks) in this cohort (Tsai et al. 2008 ). As such, our findings suggest that PTGES2 gene polymorphisms may influence the risk of PTD through an inflammatory pathway.
Among the three significantly associated SNPs in gene PTGES2 with PTD, rs4837243 and rs7047254 are located at the predicted transcription binding sites according to the bioinformatics tool FuncPred, indicating that they may have an impact on gene transcription, particularly for rs7047254. This SNP is located *2 kb upstream of the transcriptional start site for gene PTGES2, and also at a region with high regulatory potential based on sequence alignments of seven species (King et al. 2005) , and thus is likely to exhibit regulatory activity. rs4837243 is located within an intronic region *50 nt from its 5 0 splice site, and is exactly within two functional RNA elements (each with 34 nt) bound by a splicing regulator, FOX2 (Yeo et al. 2009 ). Interestingly, gene PTGES2 has at least three known alternatively spliced transcripts. Observed together, rs4837243 may play a regulatory role in alternative splicing of gene PTGES2. As such, functional studies of these significantly associated SNPs will be needed once our findings are confirmed by replication studies in different populations.
Our study has several merits. This is the first genetic association study on the fatty acid metabolism pathway and PTD, and is currently the largest candidate gene study of PTD in a black urban population in the US. We comprehensively selected functional and genotype tagSNPs for each gene, and we also imputed untyped SNPs based on both HapMap II and III data. None of the previous genetic studies of PTD have undertaken such dense SNP selection with consideration for coverage (i.e., tagSNP selection) and potential function (i.e., bioinformatics prediction). We found that 11 out of 21 significantly associated SNPs (Table 3) are not included by Illumina's Omni2.5 BeadChip, including two from the gene PTGES2 (rs7862523 and rs7047254). This may partially explain the 'missing heritability' from the genome-wide association study (GWAS), given that current commercial arrays provide a low coverage for the common variations (MAF [ 5%) in candidate genes (Bhangale et al. 2008; Li et al. 2008) , particularly in the black population. It has been demonstrated that Human1M only covers 55% of common SNPs (r 2 C 0.8) for 76 genes resequenced in HapMap African samples (Bhangale et al. 2008) . Besides the comprehensive SNP selection, the genotype imputation of the present study limits the possibility of missing a causal SNP. Finally, the permutation-based ARTP method reduces the false positive rate from multiple tests. Therefore, although the observed associations were moderate in the present study, the chance of having false positive or false negative findings was relatively low.
This current study also has limitations. A major limitation is the lack of replication; this particularly important in light of the moderate associations that we found. Thus, our findings need to be confirmed in independent studies, and furthermore, the underlying biological mechanisms need to be explored. Our study did not cover all of the important candidate genes relevant to the fatty acids metabolism pathway, for example, ELOVLs (elongase for long-chain PUFAs synthesis) and PTGERs (PGE2 receptors); these gene families may be considered in the future. Also, the joint effects of maternal and fetal genotypes should be examined in future studies. In the past decade, our team and others have demonstrated the important role of genetic susceptibility and G 9 E interactions in PTD Hao et al. 2004; Jones et al. 2010; Nukui et al. 2004; Plunkett and Muglia 2008; Romero et al. 2010; Suh et al. 2008; Tsai et al. 2008; Wang et al. 2002; Yu et al. 2009b) . The majority of these previous studies were focused on inflammatory genes, interleukins and their receptors, pathogen recognition genes, remodeling of connective tissues and response to environmental toxins, etc. Whether the SNPs evaluated in this study can interact with PUFAs measures to affect the risk of PTD (i.e., gene-fatty acid interactions) and whether imbalanced PUFAs, SNPs and epigenetic marks of the fatty acids metabolic pathway genes interact to influence the risk of PTD are important questions for future study.
In summary, we conducted a comprehensive candidate gene study of PTD in a large U.S. black population. We found a modest genetic association of fatty acid metabolism pathway gene SNPs with PTD. Our findings underscore the value in further exploring the role of gene variants involved in fatty acid metabolic pathways in PTD. Our findings also stress the need to simultaneously explore fatty acid measures, genetic variants and epigenetic marks in order to better understand the complex interplay of genetic susceptibility, dietary intake, and gene regulation on the risk of PTD.
